Swedish pharma company Meda released a statement regarding a new patent for its Astepro nasal spray that reads in its entirety:
“The United States Patent and Trademark Office (USPTO) today issued a patent related to Astepro (azelastine) nasal spray. This patent will be listed in the FDA’s Approved Drug Products List (the Orange Book). The Astepro patent is valid until 2028.”
“‘I’m delighted that the US patent for Astepro has been granted. This is great news for our azelastine franchise,’” said Anders Lönner, CEO of Meda AB.”
Astepro is “new, improved” formulation of Astelin and has been available in the US since October 2009. It is not currently available in Europe.
